Thermo Fisher Scientific CD134 (OX40) Monoclonal Antibody (ACT35 (ACT-35)), Biotin, eBioscience

Applications

Tested Dilution

Publications

Flow Cytometry (Flow)

5 µL (0.25 µg)/test

View 2 publications 2 publications

Product Specifications

Published species

Not Applicable

Host/Isotype

Mouse / IgG1, kappa

Recommended Isotype Control

Mouse IgG1 kappa Isotype Control (P3.6.2.8.1), Biotin, eBioscience™

Class

Monoclonal

Type

Antibody

Clone

ACT35 (ACT-35)

Conjugate

Biotin Biotin Biotin

View additional formats

• Unconjugated
• APC
• FITC
• PE
• PE-Cyanine7
• Request custom conjugation

Form

Liquid

Concentration

5 µL/Test

Storage conditions

4° C, do not freeze

Shipping conditions

Ambient (domestic); Wet ice (international)

RRID

AB_2815059

Product Specific Information

Description: The ACT35 monoclonal antibody reacts with human CD134, also known as OX-40. A member of the TNF receptor superfamily, CD134/OX-40 is a 50 kDa type I membrane glycoprotein expressed by activated T lymphocytes. The interaction of CD134 with OX-40L has been implicated in T cell-dependent humoral response, regulation of primary T cell expansion, survival of T cells, size of the memory T cell pool and regulation of tolerance in the CD4^+ T cell compartment.

Applications Reported: This ACT35 (ACT-35) antibody has been reported for use in flow cytometric analysis.

Applications Tested: This ACT35 (ACT-35) antibody has been pre-diluted and tested by flow cytometric analysis of stimulated normal human peripheral blood cells. This may be used at 5 µL (0.25 µg) per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test.

Target Information

OX40 is a protein receptor found on the surface of T cells, a type of white blood cell that plays a crucial role in the immune system. When activated, OX40 promotes the proliferation and survival of T cells, leading to a stronger immune response against cancer cells and infectious agents. OX40 agonists, which are drugs that activate OX40, have shown promising results in preclinical and clinical studies as a potential immunotherapy for cancer. They can enhance the efficacy of other cancer treatments such as chemotherapy and checkpoint inhibitors, and may also have applications in autoimmune diseases and allergies.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.